UCSF Health V.10 4.14.2023

UCSF Health Guidance for Discontinuing Isolation for <u>Select</u> Severely Immunocompromised COVID+ Patients

Guidelines are intended to assist with clinical decision-making but cannot replace personalized evaluation and management decisions based on individual patient factors

Select severely immunocompromised

All patients

- 1. Solid organ transplant recipient in the last year
- 2. Receiving rituximab or other B-cell depleting agents within the last 6 months
- 3. Primary immunodeficiencies combined immunodeficiencies (e.g. SCID/CVID), B-cell deficiencies and/or needing immunoglobulin replacement, idiopathic CD4 lymphopenia/severe lymphopenia; but NOT CGD or most DiGeorge's syndrome
- i. Adult AML/ALL until 3 months after completion of cytotoxic chemotherapy
- ii. Adult CAR-T cell and Allogeneic stem cell transplant within last 3 months

b. Pediatric services

a. Adult services

- i. Patients with AML until 3 months after completion of chemotherapy
- ii. Patients with infant ALL and/or ALL patients not in remission
- iii. Patients with CAR-T cell therapy within the last 3 months

Otherwise refer to the general discontinuation guidance for COVID-19 positive patients

COVID-19
positivity
should not
delay
ime-sensitive

Hospital Epidemiology and Infection Prevention (HEIP)
Moffitt-Long and Mt.Zion
Business Hours
415-353-4343 or 415-806-0269
(cell) or via Voalte 'Adult infection preventionist on call'

Mission Bay Business Hours 415-866-9242 or 415-806-0269 (cell) or via Voalte 'Peds infection preventionist on call'

